Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
Authors:
- Yu WangYWYu Wang
- Shari R. LipnerSLShari R. Lipner
Open Access
- 1 September 2020
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 6 (4) , 272-276
Abstract
Spironolactone is an off-label acne treatment that is commonly prescribed due to its low cost, efficacy, and tolerability. This study aimed to classify the most common adverse reactions associated with spironolactone in women of all ages and analyze the relative risk of hyperkalemia for different age groups. The U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database was analyzed for common adverse reactions associated with female patients taking spironolactone. Reported hyperkalemia adverse events with spironolactone were further subdivided by age group. Google Trends was used to examine public interest, and Altmetric was used to quantitate scholarly mentions of spironolactone. Yearly data were compared with adverse events in the FAERS database. The most common adverse reaction in women taking spironolactone was hyperkalemia (16.1% of all adverse events), but it was extremely uncommon in women age ≤45 years (1.9% of all hyperkalemia cases). Increased Google searches and scholarly mentions in the Altmetric database for spironolactone were also associated with increased reporting of adverse events in the FAERS database for men and women combined. Women taking spironolactone should be counseled that hyperkalemia is the most common adverse event but is uncommon in those age ≤45 years. Public and academic interest in spironolactone has increased in recent years, and although prescribing data are not available, this interest may account for the increased reporting to FAERS during the same time period.Keywords
This publication has 19 references indexed in Scilit:
- Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for AcneJAMA Dermatology, 2015
- Trimethoprim–sulfamethoxazole and risk of sudden death among patients taking spironolactoneCanadian Medical Association Journal, 2015
- European Evidence‐based (S3) Guidelines for the Treatment of AcneJournal of the European Academy of Dermatology and Venereology, 2012
- Expert Committee Recommendations for Acne ManagementPediatrics, 2006
- Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation StudyNew England Journal of Medicine, 2004
- Determinants of glomerular hypofiltration in aging humansKidney International, 2003
- Effect of Antibiotics on the Oropharyngeal Flora in Patients With AcneArchives of Dermatology, 2003
- Long-Term Safety of Spironolactone in Acne: Results of an 8-Year Followup StudyJournal of Cutaneous Medicine and Surgery, 2002
- Oral spironolactone: an effective treatment for acne vulgaris in womenBritish Journal of Dermatology, 1986
- Oral spironolactone improves acne vulgaris and reduces sebum excretionBritish Journal of Dermatology, 1984